{"id":"NCT03877510","sponsor":"Impax Laboratories, LLC","briefTitle":"Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations","officialTitle":"An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-03","primaryCompletion":"2022-03-21","completion":"2022-03-21","firstPosted":"2019-03-15","resultsPosted":"2023-06-06","lastUpdate":"2023-07-13"},"enrollment":419,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"IPX203","otherNames":[]}],"arms":[{"label":"Open Label IPX203","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events","timeFrame":"From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])","effectByArm":[{"arm":"Open Label IPX203","deltaMin":221,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":98,"countries":["United States","Czechia","France","Germany","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":419},"commonTop":["Urinary tract infection","Fall","Dyskinesia","Back pain","Constipation"]}}